September 2024 in “Journal of Cosmetic Dermatology” This study found that the topical application of DA-OTC-002, a combination of synephrine and tyramine hydrochloride, significantly reduced immediate hair shedding in women by 62.5% compared to a placebo, without any observed adverse effects.
September 2024 in “Journal of the American Academy of Dermatology” In this prospective, placebo-controlled study, the researchers observed a significant reduction in hair shedding in women after applying the combined topical treatment DA-OTC-002, containing synephrine and TAAR agonists, compared to placebo, showing a 62.5% average reduction with no reported adverse events.